Overall survival ‐ not measured · patients with paroxysmal nocturnal hemoglobinuria
1 finding from 1 review
All‐cause mortality · patients with paroxysmal nocturnal hemoglobinuria
1 finding from 1 review
Health‐related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome) · patients with paroxysmal nocturnal hemoglobinuria
1 finding from 1 review
Fatigue · patients with paroxysmal nocturnal hemoglobinuria
1 finding from 1 review
Adverse events (serious and nonserious) Medical Dictionary for Regulatory Activities (MedDRA) · patients with paroxysmal nocturnal hemoglobinuria
Eculizumab showed no clear difference in adverse events (serious and nonserious) Medical Dictionary for… compared with placebo (low certainty).
1 finding from 1 review
Transfusion independence · patients with paroxysmal nocturnal hemoglobinuria
Eculizumab probably leads to higher transfusion independence compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to any reason · patients with paroxysmal nocturnal hemoglobinuria
Eculizumab probably leads to lower withdrawal for any reason compared with placebo (moderate certainty).
1 finding from 1 review
Death · children and adults with aHUS
1 finding from 1 review
no estimate extracted
100 participants
Very low
Requirement for KRT · children and adults with aHUS
1 finding from 1 review
no estimate extracted
100 participants
Very low
Remission · children and adults with aHUS
1 finding from 1 review
no estimate extracted
100 participants
Very low
Change in eGFR · children and adults with aHUS
1 finding from 1 review
no estimate extracted
88 participants
Very low
Health‐related quality of life · children and adults with aHUS
1 finding from 1 review
no estimate extracted
100 participants
Very low
Adverse events · children and adults with aHUS
1 finding from 1 review
no estimate extracted
100 participants
Very low
Meningococcal infection · children and adults with aHUS
1 finding from 1 review
no estimate extracted
100 participants
Very low
Improvement in disability grade after 4 weeks · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
1 finding from 1 review
Improvement in disability grade Defined as achievement of a specified degree of improvement · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
Eculizumab showed no clear difference in improvement in disability grade Defined as achievement of a… compared with placebo (low certainty).
1 finding from 1 review
Time from randomisation until recovery of unaided walking · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
1 finding from 1 review
no estimate extracted
1 study · 7 participants
Low
Time from randomisation until discontinuation of ventilation (for those ventilated) · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
1 finding from 1 review
Death · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
Eculizumab showed no clear difference in death compared with placebo (low certainty).
1 finding from 1 review
Death or disability after 12 months In the absence of data at 12 months, we report the outcome at 6 months · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
It is very uncertain whether eculizumab changes death or disability after 12 months In the absence of data at 12… compared with placebo (very low certainty).
1 finding from 1 review